II. Indications
III. Mechanism
- Aryloxypropanolamine derivative
- Nonselective Beta Blocker (Beta-1 and Beta-2 Adrenergic Blockade)
- Intrinsic Sympathomimetic activity (partial beta Agonist), similar to Acebutolol
- Also blocks Serotonin (5-HT) 1A receptors, increasing available CNS Serotonin with possible Antidepressant effects
IV. Dosing
- Start: 5 mg orally twice daily
- Target: 5 to 15 mg orally twice daily
- Maximum: 60 mg/day
V. Adverse Effects
- See Beta Blocker
VI. Safety
- Pregnancy Category B
- Unknown safety in Lactation
VII. Resources
VIII. References
- (2019) Presc Lett, Resource #350503, Comparison of Oral Beta Blockers
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 66-7
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
pindolol (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
PINDOLOL 10 MG TABLET | Generic | $0.83 each |
PINDOLOL 5 MG TABLET | Generic | $0.80 each |
Ontology: Pindolol (C0031937)
Definition (NCI) | An aryloxypropanolamine derivative with antihypertensive property. Pindolol competitively binds to beta-adrenergic receptors, resulting in a decrease in beta-adrenergic activities, i.e., vasodilation, and negative chronotropic and inotropic effects. In addition, this agent blocks serotonin (5-HT) 1A receptors, thereby increasing the available serotonin in the brain. Increased serotonin levels augment the antidepressant action of selective serotonin reuptake inhibitors and monoamine oxidase inhibitors. |
Definition (MSH) | A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638) |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D010869 |
SnomedCT | 18381001, 387102009 |
LNC | LP16255-9, MTHU018207 |
English | Pindolol, Prindolol, 2-Propanol, 1-(1H-indol-4-yloxy)-3-((1-methylethyl)amino)-, 1-(1H-Indol-4-yloxy)-3-((1-methylethyl)amino)-2-propanol, pindolol, pindolol (medication), PINDOLOL, Pindolol [Chemical/Ingredient], prindolol, Prinodolol, Pindolol (product), Pindolol (substance) |
Swedish | Pindolol |
Czech | pindolol |
Finnish | Pindololi |
French | Prindolol, Pindolol |
Russian | PRINDOLOL, PINDOLOL, ПИНДОЛОЛ, ПРИНДОЛОЛ |
Japanese | プリンドロール, ブロクリンL, ブロクリン, ヒシクロピン, コカセリン, カルビスケン, カルビスケンR, パスチロン, カシムテンR, ピンドロール |
Italian | Prindololo, Pindololo |
Polish | Pindolol |
Spanish | pindolol (producto), pindolol (sustancia), pindolol, prinodolol, Pindolol, Prindolol |
German | Pindolol, Prindolol |
Portuguese | Pindolol, Prindolol |
Ontology: Visken (C0699962)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | D010869 |
French | Visken |
English | visken, Visken |